• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab.接受ixekizumab、etanercept和ustekinumab治疗的中重度银屑病患者治疗中出现的湿疹样反应的综合安全性分析。
Br J Dermatol. 2021 Oct;185(4):865-867. doi: 10.1111/bjd.20527. Epub 2021 Aug 10.
2
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.在银屑病的 7 项临床试验中，来自 ixekizumab 的短期和长期安全性结果：依那西普比较和综合数据。
J Am Acad Dermatol. 2017 Mar;76(3):432-440.e17. doi: 10.1016/j.jaad.2016.09.026. Epub 2016 Nov 23.
3
Ixekizumab vs ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: Real-world practice.治疗一年后，中度至重度银屑病患者使用司库奇尤单抗与优特克单抗实现皮肤清除的对比：真实世界实践
Dermatol Ther. 2020 Nov;33(6):e14202. doi: 10.1111/dth.14202. Epub 2020 Sep 7.
4
Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.在接受或未接受过生物疗法的中度至重度银屑病患者中使用司库奇尤单抗的治疗结果：两项III期随机研究的综合分析
J Eur Acad Dermatol Venereol. 2017 Apr;31(4):679-685. doi: 10.1111/jdv.13990. Epub 2016 Nov 2.
5
Comparative 12-week effectiveness and safety outcomes of biologic agents ustekinumab, secukinumab and ixekizumab for the treatment of plaque psoriasis: a real-world multicenter retrospective study.生物制剂优特克单抗、司库奇尤单抗和依奇珠单抗治疗斑块状银屑病的12周疗效和安全性比较：一项真实世界多中心回顾性研究。
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e416-e418. doi: 10.1111/jdv.16366. Epub 2020 May 8.
6
An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis.IXORA-S中患者报告结局的分析：中度至重度银屑病患者使用司库奇尤单抗与优特克单抗52周的比较
Acta Derm Venereol. 2020 Dec 9;100(19):adv00344. doi: 10.2340/00015555-3700.
7
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study.中度至重度银屑病中ixekizumab与依那西普或安慰剂的比较：3期随机UNCOVER-3研究中拉丁美洲患者的亚组分析。
Actas Dermosifiliogr. 2017 Jul-Aug;108(6):550-563. doi: 10.1016/j.ad.2017.02.005. Epub 2017 Mar 23.
8
Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan.真实世界中生物制剂治疗中重度斑块状银屑病的疗效：对台湾 75 例患者的分析。
PLoS One. 2020 Dec 29;15(12):e0244620. doi: 10.1371/journal.pone.0244620. eCollection 2020.
9
Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes.用于比较依奇珠单抗与依那西普和安慰剂在中重度斑块状银屑病患者中的疗效的绝对和相对银屑病面积和严重程度指数（PASI）：UNCOVER-2 和 UNCOVER-3 结局的综合分析。
Acta Derm Venereol. 2019 Oct 1;99(11):971-977. doi: 10.2340/00015555-3245.
10
The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.体重对依奇珠单抗疗效和安全性的影响：来自三项中度至重度斑块型银屑病患者随机、对照 3 期研究的综合数据库结果。
J Eur Acad Dermatol Venereol. 2017 Jul;31(7):1196-1207. doi: 10.1111/jdv.14252. Epub 2017 May 4.

引用本文的文献

1
Successful Treatment of Ixekizumab-Induced Paradoxical Eczematous Reaction with JAK Inhibitors: A Case Report.使用JAK抑制剂成功治疗司库奇尤单抗诱导的矛盾性湿疹反应：一例报告
Clin Cosmet Investig Dermatol. 2025 Sep 2;18:2133-2139. doi: 10.2147/CCID.S541725. eCollection 2025.
2
Risks of Biologic Therapy and the Importance of Multidisciplinary Approach for an Accurate Management of Patients with Moderate-Severe Psoriasis and Concomitant Diseases.生物疗法的风险以及多学科方法对于准确管理中重度银屑病及伴发疾病患者的重要性。
Biology (Basel). 2022 May 25;11(6):808. doi: 10.3390/biology11060808.
3
Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management.银屑病中的生物制剂：长期安全性与风险管理的最新观点
Psoriasis (Auckl). 2022 Jan 6;12:1-14. doi: 10.2147/PTT.S328575. eCollection 2022.

本文引用的文献

1
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature.抗白细胞介素-17 治疗过程中出现的湿疹样发疹的临床和组织病理学特征：病例系列和文献复习。
Expert Opin Biol Ther. 2020 Jun;20(6):665-672. doi: 10.1080/14712598.2020.1727439. Epub 2020 Feb 17.
2
Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review.接受生物制剂治疗斑块状银屑病患者出现湿疹样表型转换：一项系统评价
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):1440-1448. doi: 10.1111/jdv.16246. Epub 2020 Feb 27.
3
Morphologic Switch From Psoriasiform to Eczematous Dermatitis After Anti-IL-17 Therapy: A Case Series.抗白细胞介素-17治疗后银屑病样皮炎向湿疹性皮炎的形态学转变：病例系列
JAMA Dermatol. 2019 Sep 1;155(9):1082-1084. doi: 10.1001/jamadermatol.2019.1268.
4
Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition.银屑病抗白细胞介素17治疗期间出现的湿疹样皮疹：一种新出现的情况。
Br J Dermatol. 2019 Sep;181(3):604-606. doi: 10.1111/bjd.17779. Epub 2019 May 14.
5
TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis.在矛盾性银屑病中，肿瘤坏死因子阻断可诱导I型干扰素反应失调且无自身免疫现象。
Nat Commun. 2018 Jan 2;9(1):25. doi: 10.1038/s41467-017-02466-4.
6
Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).司库奇尤单抗治疗日本中重度斑块状银屑病、红皮病型银屑病和泛发性脓疱型银屑病患者的疗效和安全性：一项为期52周的开放标签3期研究（UNCOVER-J）的结果
J Dermatol. 2017 Apr;44(4):355-362. doi: 10.1111/1346-8138.13622. Epub 2016 Oct 11.
7
Events per person year. Can obscure the true risk of certain adverse drug reactions.每人每年发生的事件。可能会掩盖某些药物不良反应的真实风险。
BMJ. 1995 Jun 3;310(6992):1470. doi: 10.1136/bmj.310.6992.1470.

Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab.

作者信息

Brunner P M, Conrad C, Vender R, Grond S, Schuster C, Patel H, Xu W, Carrascosa Carrillo J M

机构信息

Department of Dermatology, Medical University of Vienna, Vienna, Austria.

Department of Dermatology, Lausanne University Hospital CHUV, Lausanne, Switzerland.

出版信息

Br J Dermatol. 2021 Oct;185(4):865-867. doi: 10.1111/bjd.20527. Epub 2021 Aug 10.

DOI:10.1111/bjd.20527
PMID:34076896
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8518506/
Abstract
摘要